International Journal of Clinical Practice

Research Article

Expression and Prognostic Value of PIK3CA, VEGF, IL-8, IL-10, and RIP2 in Diffuse Large B-Cell Lymphoma

Table 1

Comparison of VEGF, IL-8, IL-10, PIK3CA, and RIP2 in DLBCL patients with different clinical features.


Clinical features	n	VEGF (pg/mL)	IL-8 (pg/ml)	IL-10 (pg/ml)	PIK3CA positive (n)	RIP2 positive (n)

Age (years)
<60	30	554.78 ± 73.19	26.98 ± 4.21	42.78 ± 10.29	21	24
≥60	38	578.92 ± 81.12	26.01 ± 4.19	45.93 ± 10.34	20	18
χ²/t	—	−1.272	0.946	−1.250	0.716	1.249
	—	0.208	0.348	0.216	0.398	0.364

Gender
Male	37	553.23 ± 69.98	24.93 ± 7.34	44.01 ± 10.28	19	17
Female	31	563.28 ± 74.91	26.87 ± 8.27	46.93 ± 11.23	22	25
χ²/t	—	−0.571	−1.025	−1.118	0.178	2.412
	—	0.570	0.309	0.268	0.673	0.120

Ann Arbor stage
I	15	531.81 ± 36.98	29.32 ± 5.03	7.93 ± 2.01	8	8
II	17	589.77 ± 32.82	22.13 ± 5.18	27.63 ± 2.31	12	13
III	22	609.73 ± 33.98	15.78 ± 3.32	53.29 ± 6.93	8	7
IV	14	623.87 ± 34.93	9.83 ± 2.32	71.29 ± 8.31	13	14
F	—	20.981	62.297	370.785	4.192	10.954
	—	<0.001	<0.001	<0.001	0.241	0.012

Symptoms
Absence	37	547.91 ± 47.39	25.97 ± 5.32	45.92 ± 10.29	19	18
Presence	31	583.89 ± 52.93	27.22 ± 5.21	48.21 ± 10.32	22	24
χ²/t	—	−1.399	0.974	−0.913	0.494	2.412
	—	0.166	0.334	0.365	0.482	0.120

Extranodal site
≤1	37	556.28 ± 68.28	20.97 ± 4.31	42.83 ± 10.23	9	10
>1	31	597.92 ± 69.13	29.92 ± 4.23	49.13 ± 10.34	32	32
χ²/t	—	2.490	−8.601	−2.517	25.805	23.048
	—	0.015	<0.001	0.014	<0.001	<0.001

Serum LDH level (U/L)
<245	32	557.92 ± 53.21	21.23 ± 1.43	43.21 ± 10.37	10	11
≥245	36	598.78 ± 55.18	27.89 ± 1.34	49.39 ± 10.76	31	31
χ²/t	—	−2.992	−19.821	−2.321	21.048	18.319
	—	0.004	<0.001	0.024	<0.001	<0.001

IPI scores
0-1	13	521.98 ± 32.19	29.48 ± 3.07	8.38 ± 10.23	2	1
2	19	538.91 ± 36.27	22.96 ± 4.45	29.87 ± 11.34	8	7
3	22	568.92 ± 35.28	16.89 ± 3.37	52.29 ± 13.29	19	20
4-5	14	587.38 ± 37.92	12.38 ± 3.72	69.89 ± 14.43	12	14
F	—	10.022	56.705	65.52	23.602	37.672
	—	<0.001	<0.001	<0.001	<0.001	<0.001

ECOG scores
0-1	46	547.98 ± 34.98	28.93 ± 6.28	10.87 ± 1.93	19	20
≥2	22	601.98 ± 35.78	19.49 ± 8.94	67.92 ± 13.29	22	22
χ²/t	—	−5.912	5.035	−28.716	12.168	20.133
	—	<0.001	<0.001	<0.001	<0.001	<0.001

Bone marrow involvement
Presence	11	535.98 ± 67.93	12.88 ± 3.98	40.93 ± 10.24	11	10
Absence	57	586.91 ± 63.29	33.83 ± 4.34	48.93 ± 10.32	30	32
χ²/t	—	−2.416	−14.838	−2.357	8.642	4.786
	—	0.018	<0.001	0.021	0.003	0.041

Extranodal involvement
Presence	19	588.89 ± 76.98	17.91 ± 3.92	49.98 ± 10.37	16	18
Absence	49	543.78 ± 73.28	30.38 ± 3.89	43.39 ± 10.24	26	24
χ²/t	—	2.246	−11.836	2.373	5.625	12.138
	—	0.028	<0.001	0.021	0.018	<0.001

Hans
GCB	31	582.91 ± 71.29	25.99 ± 4.88	45.19 ± 12.19	17	19
Non-GCB	37	564.39 ± 75.38	27.98 ± 4.99	49.38 ± 12.39	24	23
χ²/t	—	1.034	−1.654	−1.399	0.709	0.005
	—	0.305	0.102	0.166	0.461	0.941

DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; GCB, germinal center B-cell; IPI, international prognostic index; ECOG, eastern cooperative oncology group; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; VEGF, vascular endothelial growth factor; IL, interleukin; RIP2, receptor-interacting protein-2.